Balyasny Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Balyasny Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,883	Closed	-$87K	–	2163
2020 Q4	$87K	Buy	+13,883	New	+$81.7K	﹤0.01%	1253
2020 Q2	–	Sell	-339,869	Closed	-$1.07M	–	1582
2020 Q1	$1.07M	Buy	+339,869	New	+$1.25M	0.01%	746
2018 Q3	–	Sell	-15,800	Closed	-$161K	–	2134
2018 Q2	$161K	Buy	15,800 +2,300	+17%	+$26K	﹤0.01%	1666
2018 Q1	$176K	Buy	+13,500	New	+$201K	﹤0.01%	1779
2017 Q3	–	Sell	-350,000	Closed	-$8.44M	–	2148
2017 Q2	$8.44M	Sell	350,000 -48,850	-12%	-$1.08M	0.03%	580
2017 Q1	$7.68M	Buy	398,850 +148,550	+59%	+$2.34M	0.04%	585
2016 Q4	$3.85M	Buy	+250,300	New	+$3.25M	0.02%	754

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's PRTK Position: Q1 2021 in Review

Balyasny Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2021, closing a stake of 13,883 shares — an estimated $87K sold.

Balyasny Asset Management first reported a position in PRTK in Q4 2016 and held it in 7 quarters. The position peaked at $8.44M in Q2 2017. 107 funds tracked by Wall St. Rank hold PRTK as of Q1 2021.

Balyasny Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Balyasny Asset Management sold 13,883 Paratek Pharmaceuticals, Inc. shares in Q1 2021, an estimated $87K.
Balyasny Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 7 quarters.
Balyasny Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $8.44M in Q2 2017.
107 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.